23 Sep

The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics

WRITTEN BY Sarah Collins


On September 16, 2016, Johnson & Johnson (JNJ) announced the acquisition of Abbott Medical Optics, a subsidiary of Abbott Laboratories (ABT). After this news, JNJ’s stock fell ~0.3% during the day, whereas the shares of Abbott Laboratories rose ~2%.

The acquisition will be a cash deal worth ~$4.3 billion. The deal is expected to close in the first quarter of 2017 and is estimated to be immediately accretive to JNJ’s adjusted EPS (earnings per share). Investors can gain diversified exposure to JNJ by investing in the iShares S&P 500 Growth ETF (IVW). JNJ accounts for ~1.7% of IVW’s total holdings.

The Rationale behind Johnson & Johnson’s Acquisition of Abbott Medical Optics

Abbott Medical Optics registered strong sales of around $1.1 billion in 2015 and is a profitable business segment of Abbott Laboratories. The company’s product segments include Consumer Eye Health, Cataract Surgery, and Laser Refractive Surgery.

Deal rationale

The acquisition is expected to be advantageous for both Johnson & Johnson and Abbott Laboratories. Abbott Laboratories is already undergoing consolidation, focusing on its core business segments to improve operational efficiencies and the company’s profitability. Abbott’s Medical Optics business wasn’t aligned to its core business areas and thus is an advantageous move for the company as it moves ahead with its big acquisition of St. Jude Medical (STJ) and Alere (ALR) by the end of 2016.

Ashley McEvoy, JNJ’s Vision Care Chair, stated: “Eye health is one of the largest, fastest growing and most underserved segments in health care today. With the acquisition of Abbott Medical Optics’ strong and differentiated surgical ophthalmic portfolio, coupled with our world-leading Acuvue contact lens business, we will become a more broad-based leader in vision care. Importantly, with this acquisition, we will enter cataract surgery—one of the most commonly performed surgeries and the number one cause of preventable blindness.”

In the next part, we’ll look at JNJ’s latest therapy approval by the FDA.

Latest articles

Goldman Sachs (GS) settled a lawsuit that alleged it rigged bond prices. Also, Deutsche Bank agreed to pay a fine of $15 million to settle a lawsuit.

In the November 15 premarket trading session, Amarin Corporation (AMRN) stock rose more than 7%, caused by the FDA positive decision for Vascepa.

In the November 14 trading session, Aurora Cannabis (ACB) stock fell 12.7% from the previous session during after-hours trading.

Strategy Analytics reported that Apple could lead the 5G smartphone market in 2020, outshining Samsung—the current leader in the global 5G market.

This week has been tough for the cannabis sector. Cronos Group and Canopy Growth reported lower-than-expected earnings, and the sector ETFs dropped.

Yesterday, Argus Research upgraded Uber stock from “hold” to “buy.” Let's look at Uber and Lyft’s recent analyst rating changes.